Alzheimer's drug that slows decline given green light in UK - but won't be available on NHS
A key clinical trial has shown lecanemab can slow the decline in memory and mental agility by 27% in patients with mild Alzheimer's. But it can also cause swelling and bleeding in the brain of some patients.
Thursday 22 August 2024 10:34, UK
